58 Results for "

Focal adhesion kinase (FAK)

" in MedChemExpress (MCE) Product Catalog:
Products (58)

58 Results for "Focal adhesion kinase (FAK)" in MCE Product Catalog:

31
31 Publications Verification
Cat. No.: HY-12444
CAS No.: 4506-66-5
Purity:  ≥98.0%
Synonyms: FAK Inhibitor 14
Target:  

FAK

Research Areas:  

Cancer

Y15 is a potent and specific inhibitor of focal adhesion kinase (FAK) that inhibits its autophosphorylation activity, decreases the viability of cancer cells, and blocks tumor growth.
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-100498A
CAS No.: 1416771-10-2
Purity:  99.89%
Target:  

FAK Apoptosis

Research Areas:  

Cancer

GSK-2256098 hydrochloride is a focal adhesion kinase (FAK) inhibitor that exhibits potential antiangiogenic and antineoplastic activities. GSK-2256098 hydrochloride targets FAK to inhibit tumor cell growth by regulating cell adhesion, migration, proliferation, and survival.
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-N1372A
CAS No.: 436-77-1
Fangchinoline is isolated from Stephania tetrandra with extensive biological activities, such as enhancing immunity, anti-inflammatory sterilization and anti-atherosclerosis. Fangchinoline, a novel HIV-1 inhibitor, inhibits HIV-1 replication by impairing gp160 proteolytic processing . Fangchinoline targets Focal adhesion kinase (FAK) and suppresses FAK-mediated signaling pathway in tumor cells which highly expressed FAK . Fangchinoline induces apoptosis and adaptive autophagy in bladder cancer .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-10460
CAS No.: 717906-29-1
Purity:  99.74%
Target:  

Pyk2 FAK

Research Areas:  

Cancer

PF-431396 is an orally active dual focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2) inhibitor, with IC50 values of 2 nM and 11 nM, respectively .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-122844
CAS No.: 1227948-82-4
Purity:  99.66%
Synonyms: BI-853520; IN-10018
Target:  

FAK

Research Areas:  

Cancer

Ifebemtinib (BI 853520) is an orally active and potent focal adhesion kinase (FAK) inhibitor (recombinant FAK IC50=1 nM). Ifebemtinib shows anti-proliferative activity against cancer cells. Ifebemtinib inhibits FER Kinase and FES Kinase with IC50s of 900 nM and 1040 nM, respectively .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-122844A
Synonyms: BI-853520 hydrochloride; IN-10018 hydrochloride
Target:  

FAK

Research Areas:  

Cancer

Ifebemtinib (BI-853520) hydrochloride is an orally active and potent focal adhesion kinase (FAK) inhibitor (IC50 = 1 nM for recombinant FAK). Ifebemtinib hydrochloride exhibits antiproliferative activity against cancer cells .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-132296
CAS No.: 2743427-26-9
Purity:  99.26%
Target:  

FAK PROTACs

Research Areas:  

Cancer

GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader with a pDC50 of 8.4. GSK215 is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718. GSK215 induces rapid and prolonged FAK degradation, giving a long-lasting effect on FAK levels and a marked pharmacokinetic/pharmacodynamics (PK/PD) disconnect .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-128580
CAS No.: 2354405-14-2
Purity:  98.26%
Target:  

FAK

Research Areas:  

Cancer

FAK inhibitor 2 is a potent focal adhesion kinase (FAK) inhibitor with an IC50  of 0.07 nM, with antitumor and anti-angiogenesis activities .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-145652
CAS No.: 1393653-34-3
Purity:  99.86%
Synonyms: AMP-945
Narmafotinib (AMP-945) is an orally active inhibitor of the enzyme focal adhesion kinase (FAK, KD=0.21 nM). Narmafotinib inhibits autophosphorylation of 397Y-FAK in MDA-MB-231 cells with an IC50=7 nM and exhibits low general cellular toxicity (IC50=2.7 μM, MDA-MB-231 cells). Narmafotinib can be used for anti-cancer study .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-15357
CAS No.: 761436-81-1
Purity:  99.62%
Research Areas:  

Cancer

ALK inhibitor 1 (compound 17) is a potent pyrimidin ALK inhibitor. ALK inhibitor 1 is a potent inhibitor of testis-specific serine/threonine kinase 2 (TSSK2; IC50=31 nM) and focal adhesion kinase (FAK; IC50=2 nM) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P80460
Synonyms: FAK, FAK1, PTK2, Focal adhesion kinase 1, FADK 1, Focal adhesion kinase-related nonkinase, Protein phosphatase 1 regulatory subunit 71, Protein-tyrosine kinase 2, p125FAK, pp125FAK, FRNK, PPP1R71

Host:  

Rabbit

Application:  

WB, ICC/IF

Reactivity:  

Human, Mouse

loading...
    loading...
Cat. No.: HY-15358
CAS No.: 761438-38-4
Purity:  99.57%
Research Areas:  

Cancer

ALK inhibitor 2 (compound 18) is a potent pyrimidin ALK inhibitor. ALK inhibitor 2 is a potent inhibitor of testis-specific serine/threonine kinase 2 (TSSK2; IC50=37 nM) and focal adhesion kinase (FAK; IC50=5 nM) .
loading...
    loading...
Cat. No.: HY-144448
CAS No.: 2872588-02-6
Purity:  98.27%
Target:  

FAK Apoptosis

Research Areas:  

Cancer

FAK-IN-2 is a potent and orally active focal adhesion kinase (FAK) inhibitor, with anticancer activity (FAK IC50= 35 nM). FAK-IN-2 covalently inhibits the autophosphorylation of FAK in a dose-dependent manner, and inhibits the clone formation and migration of tumor cells, inducing apoptosis .
loading...
    loading...
Cat. No.: HY-P1189
CAS No.: 154303-05-6
Echistatin is a naturally derived RGD-containing snake venom peptide. Echistatin exhibits an IC50 of 0.6 nM against mouse αvβ3 integrin, and acts as an antagonist against αvβ3, αII3, α5β1 integrins, pp125 FAK and paxillin. Echistatin reduces the phosphorylation of pp125 FAK and paxillin, inhibits the autophosphorylation and kinase activity of pp125 FAK, and weakens its binding to pp60src and paxillin. Echistatin disrupts the actin cytoskeleton and focal adhesions, induces melanoma cell detachment from fibronectin, and regulates cell adhesion and motility. Echistatin inhibits osteoclast maturation and migration, bone resorption, platelet aggregation, bone loss, as well as adhesion and metastasis of Lewis lung cancer cells; it also increases the number of osteoclasts and bone coverage area in mice with secondary hyperparathyroidism. Echistatin can be used in research related to melanoma, lung cancer and secondary hyperparathyroidism .
loading...
    loading...
Cat. No.: HY-P1189A
Echistatin TFA is a naturally derived RGD-containing snake venom peptide. Echistatin TFA exhibits an IC50 of 0.6 nM against mouse αvβ3 integrin, and acts as an antagonist against αvβ3, αII3, α5β1 integrins, pp125 FAK and paxillin. Echistatin TFA reduces the phosphorylation of pp125 FAK and paxillin, inhibits the autophosphorylation and kinase activity of pp125 FAK, and weakens its binding to pp60src and paxillin. Echistatin TFA disrupts the actin cytoskeleton and focal adhesions, induces melanoma cell detachment from fibronectin, and regulates cell adhesion and motility. Echistatin TFA inhibits osteoclast maturation and migration, bone resorption, platelet aggregation, bone loss, as well as adhesion and metastasis of Lewis lung cancer cells; it also increases the number of osteoclasts and bone coverage area in mice with secondary hyperparathyroidism. Echistatin TFA can be used in research related to melanoma, lung cancer and secondary hyperparathyroidism .
loading...
    loading...
Cat. No.: HY-155439
CAS No.: 2766666-22-0
Purity:  99.81%
Target:  

FAK

Research Areas:  

Cancer

FAK-IN-14 (compound 8d) is a focal adhesion kinase(FAK) inhibitor with an IC50 value of 0.2438 nM. FAK-IN-14 induces U87-MG cell early apoptosis and arrest the cell at the G2/M phase .
loading...
    loading...
Cat. No.: HY-161633
CAS No.: 3034244-71-5
Target:  

PROTACs EGFR FAK

Research Areas:  

Cancer

PROTAC EGFR degrader 11 (Compound B71) is a PROTAC degrader for epidermal growth factor receptor (EGFR), with DC50 <100 nM. PROTAC EGFR degrader 11 binds CRBN-DDB1 with a Ki of 36 nM. PROTAC EGFR degrader 11 degrades EGFR, focal adhesion kinase (FAK), and RSK1, inhibits the proliferation of BaF3 wild type and EGFR mutants, with IC50 <100 nM.
loading...
    loading...
Cat. No.: HY-172888
Research Areas:  

Cancer

SPP-037 is an orally active and selective inhibitor of ST6GAL1 (IC50 = 3.59 μM). SPP-037 inhibits integrin α2,6-sialylation and integrin-FAK-paxillin pathway. SPP-037 inhibits cancer cell proliferation, migration and exhibits antiangiogenic activity. SPP-037 has anti-tumor activity in MDA-MB-231 xenograft mouse model. SPP-037 can be used for the research of triple-negative breast cancer .
loading...
    loading...
Cat. No.: HY-179512
CAS No.: 2414478-45-6
Target:  

PROTACs FAK

Research Areas:  

Cancer

BSJ-04-146 is a highly efficient and selective PROTAC targeting focal adhesion kinase (FAK) inhibitor(IC50 = 26 nM). BSJ-04-146 achieves rapid and potent FAK degradation with high proteome-wide specificity in cancer cells and induces durable degradation in mice. BSJ-04-146 binds FAK and requires the ubiquitin-proteasome machinery to achieve FAK degradation. BSJ-04-146 can be used for the study of pancreatic cancer and triple-negative breast cancer .
loading...
    loading...
Cat. No.: HY-164527
CAS No.: 1640012-88-9
Target:  

Src FAK EGFR

Research Areas:  

Cancer

Si306 is a Src inhibitor with antitumor activity. Si306 reduces the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), and inhibits the invasion of human glioblastoma (GBM) .
loading...
    loading...